Dr. Fei Tian

LPX50 constituent company, HBM Healthcare Investments AG has announced a successful exit from Yellow Jersey Therapeutics for USD 1.25 billion. HBM Healthcare Investments expects a cash inflow of approximately USD 78 million and the increase in NAV per share by CHF 8.70 ( 3.5%). HBM Healthcare Investments invests in the healthcare sector. It holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology, diagnostics sectors and related areas. Johnson & Johnson will acquire global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD). 🔷 Link to official press release 👉 https://lnkd.in/dQXD-3iW 🔷 Subscribe to Listed Private Equity Barometer published by LPX AG 👉 https://lnkd.in/ex-E8nej Disclaimer: This content is provided for informational purposes and none of the content here should be construed as financial advice or an offer or solicitation for securities. The content is not intended to provide a sufficient basis on which to make an investment decision. The past performance is not indicative of future results. #privateequity #alternativeinvestments #infrastructure #privatemarkets #investments #listedprivateequity #privatedebt #privatecredit #pharmaceutical #medicine #health #Therapeutics

Afinum acquires a majority stake in evitria Abolon was mandated by Afinum Management GmbH, the DACH-based private equity firm, on its acquisition of a majority stake in Swiss biotech company evitria AG, which provides custom antibodies for research purposes. evitria has been conducting more than 30,000 transfections and has been producing more than 5,000 different antibodies to date. The company’s success is based on a unique, highly standardized and automatized production process that minimizes throughput times and guarantees high concentrations and quality levels, thereby perfectly addressing its customers’ need for specific, tailor-made antibodies. Its business model has allowed evitria to build a reputation of a superior biotech specialist and trustworthy outsourcing partner. The transaction has been closed in December 2018. The enterprise value was not made publicly available. Abolon Group was exclusively mandated by Afinum.

Roche is collaborating with Ascidian Therapeutics to develop #genetherapies for challenging #neurologicaldiseases. This move helps Roche diversify as it faces declining #oncology sales. Key Points: ▶ Innovation - Utilizing Ascidian's RNA exon editing technology. ▶ Financials - $42M initial payment, up to $1.8B in milestone payments, plus royalties. ▶ Impact - Advancing treatments with reduced risks compared to traditional gene therapy.